Overall survival for the overall real-world cohort and GARNET cohort (before and after matching)
| Overall real-world cohort (n=999) | GARNET (dostarlimab) cohort | ||||
| Before matching (n=153) | Scenario 1 (ESS=18) | Scenario 2 (ESS=62) | Scenario 3 (ESS=67) | ||
| Median OS, months (95% CI) | 10.3 (9.2 to 11.1) | NE (27.1 to NE) | 27.1 (6.4 to NE) | 40.5 (19.4 to NE) | 39.9 (21.6 to NE) |
| OS rate (95% CI) | |||||
| 6 months | 0.70 (0.67 to 0.73) | 0.85 (0.78 to 0.90) | 0.88 (0.72 to 0.95) | 0.88 (0.78 to 0.93) | 0.91 (0.83 to 0.95) |
| 12 months | 0.44 (0.40 to 0.47) | 0.73 (0.65 to 0.80) | 0.59 (0.29 to 0.80) | 0.75 (0.62 to 0.84) | 0.78 (0.66 to 0.86) |
| 18 months | 0.29 (0.26 to 0.32) | 0.67 (0.58 to 0.74) | 0.56 (0.28 to 0.77) | 0.70 (0.57 to 0.80) | 0.69 (0.56 to 0.79) |
| HR for OS (95% CI) | – | 0.32 (0.24 to 0.42) | 0.47 (0.22 to 0.99) | 0.30 (0.20 to 0.47) | 0.31 (0.21 to 0.46) |
| P-value | – | <0.0001 | 0.0481 | <0.0001 | <0.0001 |
Scenario 1: Matching variables are histology, grade, and number of prior platinum-based therapies; scenario 2: Matching variables are histology and number of prior platinum-based therapies; scenario 3: Matching variables are race, histology, stage at initial diagnosis, and surgery (ECOG PS was not included as a matching variable due to patients with unknown status).
ECOG PS, Eastern Cooperative Oncology Group Performance Status; ESS, effective sample size; NE, non-estimable; OS, overall survival.